Abstract 14P
Background
Host tumor microenvironment (TME) assessment is considered to play an important role in the prognostic and therapeutic predictions of breast cancer treatment. No consensus has been reached regarding evaluation methods despite reports of the utilization of tumor-infiltrating lymphocytes (TILs) for tumor immune microenvironment (TIME) monitoring. While the International Working Group recommends a tumor stromal evaluation, the timing of TIME assessment has not yet been established. Here, we focused on the assessment time and verified clinical predictions of neoadjuvant chemotherapy (NAC) effects using TILs.
Methods
Two hundred thirty-nine patients were treated with neoadjuvant chemotherapy (NAC). During the period from diagnostic needle biopsy to NAC initiation for breast cancer, the optimal evaluation timing was examined using a receiver operating characteristic (ROC) curve analysis.
Results
The prognostic analysis revealed that both disease-free survival (DFS) and overall survival (OS) were significantly prolonged in the short-term group (118 patients) relative to the long-term group (121 patients) (p = 0.020, p = 0.010, log-rank). A significant correlation between TILs and pathological complete response (pCR) was only observed in the short-term group (p = 0.033). Prognostic analysis revealed that in the short-term group, the high TIL group had a significantly better survival prognosis relative to the low TIL group (DFS: p = 0.001, OS: p = 0.021, log-rank). TILs were also found to be a significant factor affecting DFS in the univariate analysis (p = 0.004, hazard ratio = 0.115), as well as an independent factor affecting the DFS in a multivariate analysis (p = 0.008, hazard ratio = 0.130).
Conclusions
The timing of TIL assessment during NAC for breast cancer may be more sensitive index in the short term (≤35 days).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract